ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$13.58 USD
-0.18 (-1.31%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $13.73 +0.15 (1.10%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ADMA 13.58 -0.18(-1.31%)
Will ADMA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ADMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADMA
Adma Biologics (ADMA) Stock Moves -1.31%: What You Should Know
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
ADMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics
Other News for ADMA
Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock 'Hand Over Fist'
Leslie's Issues Preliminary Financial Results, Joins Beyond Meat, Domino's And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights
Adma Biologics price target raised by $2 at Mizuho, here's why
Wall Street Breakfast: The Week Ahead